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http://www.molecular-cancer.com/content/13/1/177RESEARCH Open AccessCirculating mouse Flk1+/c-Kit+/CD45- cells function
as endothelial progenitors cells (EPCs) and
stimulate the growth of human tumor xenografts
Jeffery S Russell1* and J Martin Brown2Abstract
Background: Endothelial progenitor cells (EPCs) have been demonstrated to have stem-cell like as well as mature
endothelial functions. However, controversy remains as to their origins, immunophenotypic markings, and contribution
to the tumor vascular network and tumor survival.
Methods: Flow cytometric analysis and sorting was used to isolate Flk-1+/c-Kit+/CD45- cells. Matrigel and methycellulose
assays, flow cytometry, and gene array analyses were performed to characterize several murine EPC cell populations.
Human tumor xenografts were used to evaluate the impact of EPCs on tumor growth and vascular development.
Results: Flk-1+/c-Kit+/CD45- cells were present at low levels in most murine organs with the highest levels in adipose,
aorta/vena cava, and lung tissues. Flk-1+/c-Kit+/CD45- cells demonstrated stem cell qualities through colony
forming assays and mature endothelial function by expression of CD31, uptake of acLDL, and vascular structure
formation in matrigel. High passage EPCs grown in vitro became more differentiated and lost stem-cell markers.
EPCs were found to have hemangioblastic properties as demonstrated by the ability to rescue mice given whole
body radiation. Systemic injection of EPCs increased the growth of human xenograft tumors and vessel density.
Conclusions: Flk-1+/C-Kit+/CD45- cells function as endothelial progenitor cells. EPCs are resident in most
murine tissue types and localize to human tumor xenografts. Furthermore, the EPC population demonstrates
stem-cell and mature endothelial functions and promoted the growth of tumors through enhanced vascular
network formation. Given the involvement of EPCs in tumor development, this unique host-derived population
may be an additional target to consider for anti-neoplastic therapy.
Keywords: Vasculogenesis, Endothelial progenitor cell, Angiogenesis, Tumor, Microenvironment, Therapy,
ResistanceBackground
In 1997, Asahara and colleagues identified a monocytic
population of adult human CD34+ cells that demon-
strated clonogenicity as well as contributed to neovascu-
larization within ischemic areas [1]. Similarly, Gill et al.
demonstrated the rapid mobilization of Flk-1+/AC133+
cells into the peripheral blood after vascular trauma
which coated artificial blood vessel grafts [2]. These re-
sults suggested the presence of a circulating endothelial
progenitor cell (EPC) population with both stem-cell like* Correspondence: jeffery.russell@moffitt.org
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article, unless otherwise stated.qualities and mature endothelial function. While angio-
genesis requires the sprouting and proliferation of local
endothelial cells, vasculogenesis is the de novo formation
of blood vessels from circulating endothelial precursor
cells. EPCs are thought to be recruited through the cir-
culation by an incompletely defined cytokine-mediated
pathway to sites of vascular injury or hypoxia. In
addition to self-renewal, EPCs differentiate into mature
endothelial cells and release proangiogenic cytokines
and growth factors in order to form new blood vessels
and/or incorporate into existing vasculature [3-5].
The potential for adult peripheral blood to contain a
cellular subpopulation with the ability to repair damaged
vasculature has generated intense interest in this field.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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disease, peripheral vascular disease, myocardial infarc-
tion, pulmonary diseases, and potentially the many com-
plications of diabetes could benefit from a renewable cell
population that repairs damaged vasculature [6-12]. How-
ever, malignant tumors may exploit these “beneficial”
EPCs in order to obtain oxygen, growth factors and
other nutrients, expand the tumor vasculature as well
as to provide access to other sites of growth, resulting
in metastatic spread of the disease [13-15]. Thus, vas-
cular recovery via a circulating EPC mechanism may
be a parallel or backup pathway to the well-defined
angiogenesis pathway [3,16,17]. The existence of a sec-
ondary network for tumor blood vessel generation and/or
maintenance may be partially responsible for resistance
mechanisms to anti-neoplastic therapies and the limited
clinical benefit seen using anti-angiogenic inhibitors
[18-21].
Unfortunately, even with a decade and a half a research
there remains significant controversy with regard to EPCs
as well as many unanswered questions [13,22-26]. First,
which immunophenotypic markers define this population?
Second, what is the origin of these cells and how are they
recruited to areas of vascular damage? And finally, with
respect to oncology, what is the contribution of endothe-
lial progenitor cells to tumor vascular networks and tumor
growth and how might this affect resistance to anti-cancer
therapies?
We have selected immunophenotypic markers to de-
fine a cell population that was not of hematopoietic ori-
gin (CD45 negative), but would demonstrate endothelial
features (Flk-1/VEGFR-2+) as well as a stem cell marker
(c-Kit+). Prior reports have suggested that this core
phenotype (endothelial marker, stem cell marker, and
not derived from hematopoietic cell lines) is able to se-
lect for EPCs [27-31]. Our goal in this study was to
identify a population of EPCs in a murine model and
to manipulate this population using ex vivo techniques
to characterize their function. Additionally, we wanted
to determine if EPCs were present in in vivo human
tumor xenografts and to investigate their role in tumor
growth and tumor vascularization. Finally, we have
made several novel observations with regards to EPCs,
including: the wide spread distribution of EPCs in a
variety of mouse organs, established ex vivo culture
conditions for EPCs, determined that EPC localization
to solid tumors is independent of tumor type, and that
Flk-1+/c-Kit+/CD45- cells can rescue lethally irradiated
animals.
Results
Isolation of Flk-1+/c-Kit+/CD45- EPC Cells
Mouse tissue were isolated and homogenized to generate
a single cell suspension as described. Cells were analyzedby flow cytometry by first gating on single cells and then
on viable cells. Samples were then processed in a se-
quential manner to isolate cells that were positive for
the endothelial marker Flk-1 (VEGFR2), then for the
stem cell marker c-Kit positive fraction. The dual popu-
lation of Flk-1+/c-Kit+ cells was then analyzed for CD45
expression and only those cells that were CD45 negative
were selected for further assays. Figure 1A and B dem-
onstrate isolation of unstained mouse aorta/vena cava
suspensions and isotype control samples which do not
show any viable populations of Flk-1+/c-Kit+/CD45-
cells, as expected. Figure 1C demonstrates mouse aorta/
vena cava samples with a small “tail” population positive
for Flk-1. The Flk-1 positive fraction of cells demonstrated
higher levels of c-Kit + staining, and when this subset of
cells was analyzed for CD45, slightly less than half the
cells were CD45 negative. Similar results were obtained
for normal mouse lung tissue, Figure 1D. Overall, the Flk-
1+/c-Kit+/CD45- cells made up a very small population of
the total number of cells analyzed from the tissue; as seen
in Figure 1E, quantification of this population showed it
to be approximately 0.5% of the total cellular population.
Given the small quantities of cells isolated from the mouse
aorta/vena cava and lung samples, we screened a wide var-
iety of mouse tissues in order to determine which or-
gans would provide the highest yield of cells. Figure 1F
shows that the adipose, aorta/vena cava and lung sam-
ples were the highest yielding tissues. Tissue such as
brain, liver, muscle, and blood had the lowest levels of
Flk-1+/c-Kit+/CD45- cells. Interestingly, the collected
mouse adipose tissue had the highest level of Flk-1+/c-
Kit+/CD45- cells found; however, subcutaneous fat was
difficult to obtain from the young nude mice used in this
study and fat collections from 3 different nude mice were
used to generate one “sample” of fat tissue and three sam-
ples were then used for analysis. Furthermore, only 50,000
cells could be isolated from this conglomerate adipose tis-
sue sample for FACS analysis in contrast to the 100,000
cells readily available from the other tissues.
After the identification of a small resident population
of Flk-1+/c-Kit+/CD45- cells within most mouse organs,
we determine whether human tumor xenografts also had
baseline levels of this cellular subpopulation. A similar
FACS analysis was performed on several human tumor
xenografts. As shown in Figure 2A, in vitro samples of
U251 human glioma cells were not reactive to either
anti-mouse or anti-human antibodies. However, using
in vivo U251 tumors, mouse antibodies directed against
Flk-1+/c-Kit+/CD45- populations found baseline levels
of approximately 0.35%. Anti-human antibodies directed
against the same markers did not react with any cells,
indicating that the population of interest was derived
from the host animal and not derived from the tumor cells
themselves. Further experiments (Figure 2B) demonstrated
Figure 1 (See legend on next page.)
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Figure 1 Flow cytometry on normal nude mouse tissues after gating for viable, single cells and the sequential isolation of
Flk-1+/c-Kit+/CD45- cells. Representative images for cell isolation: (A) Unstained cells (B) Isotype controls (C) Isolated Aorta (D) Isolated Lung
(E) Quantification of %EPCs found by flow cytometry of mouse aorta and lung tissues (n=3) (F) Quantification of %EPCs found by flow cytometry in
selected mouse tissues (n=3-4) *Note: adipose tissue was collected from 3 different mice to generate a single sample (50,000 cells) and 3 separate
samples were analyzed.
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A549 lung carcinoma and UMSCC-1 head and neck
carcinoma cell line at approximately 1.45% and 1.40%,
respectively, compared to approximately 0.50% found
in the U251 human glioma cell lines. This result suggested
that the resident population of Flk-1+/c-Kit+/CD45- cells
is tumor type independent.
Characterization of Flk1+/c-Kit/CD45- EPC cells
We performed additional studies to determine if the selected
subpopulation of Flk-1+/c-Kit+/CD45- cells demonstrated
characteristics consistent with endothelial progenitor cells.
Figure 3A (panel 1) demonstrates the membrane labeling of
CD31, a known extracellular membrane marker of mature
endothelial cells, as well as the peri-nuclear uptake ofFigure 2 %EPCs in tumor xenografts: (A) %EPCs isolated from U251 c
based on antibody source (n=3) (B) %EPCs harvested from human tum
head and neck cancer) samples (n=3).acetylated low density lipoprotein (acLDL), which is
readily taken up by the HUVECs endothelial cell con-
trol line. Figure 3A (panel 2) demonstrates that the
tumor cell line A549 does not show the CD31 mem-
brane marker or uptake of acLDL. From our flow cy-
tometry studies we were able to isolate the mouse lung
tissue Flk-1+/c-Kit+/CD45- cell line and grow them in
culture. This initial population was referred to as the
EPC cell line. As seen in Figure 3B (panel 1), only
about 10-20% of these cells have the CD31 marker and
acLDL dual-labeling. As the acLDL fluorescent marker
is non-toxic to cells, we took the acLDL-labeled EPC
cell line, trypsinized the cells, and re-analyzed them by
flow cytometry to select for an enriched population of
acLDL + cells. As seen in Figure 3B (panel 2), theells in vitro and in vivo tumor xenografts samples and reactivity
or cell line xenografts (U251 Glioma, A549 Lung, and UMSCC1
Figure 3 Functional characteristics of isolated EPC cell lines. (A) Acetylated LDL uptake in control cell lines: panel 1) HUVECs, panel 2) A549
Lung; red – CD31, green – acLDL (B) Acetylated LDL uptake in insolated EPC cell lines: panel 1) EPC, panel 2) EPC_acLDL, panel 3) EPC_late;
red – acLDL, green – CD31 (C) Colony forming assay in methylcellulose with control cell lines: panel 1) mouse bone marrow samples, panel
2) A549 Lung cancer (D) Colony forming assay in methylcellulose with isolated EPC cell lines: panel 1) EPC, panel 2) EPC_acLDL, panel 3)
EPC_late (E) Matrigel assay with control cell lines: panel 1) HUVECs, panel 2) A549 (F) Matrigel assay with isolated EPC cell lines: panel 1)
EPC, panel 2) EPC_acLDL, panel 3) EPC_late.
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acLDL. This enriched population is referred to as the
EPC_acLDL cell line. Finally, when the EPC_acLDL cell
line approached passages 16–20, the morphology of the
cells changed to a more flat appearance, but the cell mem-
branes still labeled with CD31 and continued to demon-
strate peri-nuclear uptake of acLDL (Figure 3B, panel 3).
We refer to this high passage cell line as the EPC_Late cell
line. Thus all three isolated EPC cell lines demonstrated
CD31+ staining and uptake of acLDL, both known charac-
teristics of mature endothelial cells.Additionally, we also sought to determine if our iso-
lated cells lines demonstrated stem-cell like characteris-
tics suggestive of self-replication. Figure 3C (panel 1)
demonstrates that isolated mouse bone marrow grown
in methylcellulose media had colony forming ability. In
contrast, Figure 3C (panel 2) demonstrates the A549
tumor cell line generates a typical flat growth morph-
ology, but does not generate the cluster-like cell forma-
tions seen in the control mouse bone marrow samples.
Our generated cell lines (EPC and EPC_acLDL) demon-
strate cell-cluster formations consistent with the ability
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respectively). Interestingly, the EPC_Late cell line dem-
onstrated only the flat growth morphology with no
cluster-like formations (Figure 3D, panel 3). Additionally,
stem cell marker studies using alkaline phosphatase ana-
lysis and Oct-1 immunofluorescence were negative in all
three cell lines (data not shown). Finally, a classic marker
of endothelial function is the ability to form capillary-like
structures when grown on matrigel coated plates. Figure 3E
demonstrates the formation of capillary-like structures
from HUVECs (panel 1) and lack of these structures in the
A549 cell line when grown on matrigel. All three of our
isolated cell lines (EPC, EPC_acLDL, and EPC_Late) were
all able to generate capillary-like structures on matrigel
plates.
After generating the three cell lines as above, we then
checked the cell lines for the original markers they were
selected for to determine if these markers stayed intact
in vitro or changed over time. Figure 4A demonstrates
that the EPC cell line had low levels of Flk-1 expression,
low levels of c-Kit expression, no significant CD45
expression, and high levels of CD31 expression. The
enriched population, EPC_acLDL, demonstrated in-
creased Flk-1 expression, enhanced c-Kit expression,Figure 4 Immunophenotype markers on sorted mouse EPCs after cul
control’ Blue, samples.no significant CD45 expression, but maintained high
CD31 expression. Finally, our high passage popula-
tion, EPC_Late, demonstrated Flk-1 expression, lower
levels of c-Kit, no significant CD45 expression, and
also maintained CD31 expression. These results sug-
gest that the EPC_acLDL cell line is enriched for EPC
functionality and that the EPC_Late population has a
more mature endothelial phenotype, but may have
less stem-cell like properties.
EPCs demonstrate hemangioblastic function
EPC are considered to give rise to mature endothelial
cells but also maintain the ability to self-replicate. How-
ever, EPCs are assumed to be downstream of a hemangio-
blast cell line and should be independent of hematopoietic
cell lines. Thus, we undertook a negative study of our EPC
cell lines to determine if they had the ability to repopulate
the hematopoietic cell lines after lethal whole body irradi-
ation. In Figure 5A, 9 Gy of whole body radiation (2 ×
4.5 Gy, given 4 h apart) resulted in over 90% animal death
on day 20. However, if normal healthy marrow (3×106
cells) was transplanted by retro-orbital injection 2 hrs after
the final dose of radiation, then 100% survival was
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Figure 5 Mouse survival after whole body radiation: (A) Survival
after 9 Gy whole body radiation of nude mice with and without
bone marrow transplant (n=10, each arm) (B) Survival after 9 Gy
whole body radiation of nude mice with systemic transplant of
EPC, EPC_acLDL, and EPC_late cell lines (n=10, each arm).
Figure 6 Gene arrays: Heat map for self-organizing clusters for
isolated EPC (passage 3-6), EPC_acLDL (passage 3-6), and
EPC_late cell lines (passage 16-20). (3 samples each, performed
in duplicate).
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function; however, Figure 5B demonstrates that trans-
plantation of 3×106 cells of either the EPC cell line or the
EPC_acLDL cell line were able to protect the animals
from death and restore hematopoiesis. Interestingly, the
EPC_Late cell line was only able to keep approximately
60% of the animals alive after whole body radiation, con-
sistent with the above data that the EPC_Late cell line
lacks some of the stem-cell characteristics demonstrated
by the other isolated EPC cell lines.
EPCs genetic similarity
In order to compare our isolated cell lines genetically,
we performed a single-bead gene array analysis
(Illumina, San Diego, CA) on mouse reference slides and
found only 126 genes differentially regulated between
the three cell lines (Figure 6A). Clustering studies
showed that the EPC and EPC_acLDL cell lines ap-
peared more closely related than the high passage
EPC_Late cell line. A full list of genes up and down reg-
ulated between the cell lines is presented in Table 1.
One gene of potential interest, Sox2 - often associated
with stemness, was down regulated in the EPC_acLDL
(3.6 fold) and EPC_Late (4.7 fold) samples as compared
to the EPC parental cell line. A similar set of genes were
up and down regulated between the EPC and EPC_acLDLcell lines and a greater variety of genes were changed in
the EPC_Late cell line versus the EPC parental cell line.
These data indicate a close relationship between all three
cell lines and that the EPC_Late population is a more ma-
ture cell line with less stem cell-like characteristics.
EPCs effects on the growth of human tumor xenografts
Finally, we wanted to determine if circulating EPCs
could enhance tumor growth. First, we co-injected U251
tumor cells (3×106) with the EPC_acLDL cell line
(3×105) at a 10:1 ratio. Figure 7A demonstrates that local
co-injection of the two cell lines enhanced tumor growth
and increased the efficiency of tumor take (3/5 tumors
[60%] in mice with U251 cells only and 5/5 tumors
[100%] in the combined U251/EPC_acLDL mixture).
Thus EPC appear to enhance tumor growth in a human
xenograft model. However, local co-injection does not
reflect a physiological situation. Therefore, we injected
the EPC_acLDL cell line (3×105 cells) systemically at
7 days after the original tumor was implanted subcuta-
neously (3×106 cells). As seen in Figure 7B, systemic in-
jection of EPC_acLDL cells enhanced tumor growth as
compared to PBS vehicle controls. To evaluate the im-
pact of EPC_acLDL injection on vascular growth, we
stained tumor samples from the growth curve samples
at day 28 using CD31 as a marker of endothelial cells
and blood vessels. Figure 7C demonstrates increased
numbers of blood vessels in the animals with the
Table 1 Gene array results of EPC cell lines
EPC_acLDL v EPC EPC_late v EPC EPC_Late v EPC_acLDL
Up Down Up Down Up Down
LOC100041835 Ppa2 LOC100041835 Gadd45a Cldn1 Idh3b
Trim41 Abcb9 LOC100044129 BC038613 Olfr884 Bcl6
Gch1 Olfr1353 H3f3a Krt8 Zdhhc9 Nudcd1
Aldh5a1 Ubxn11 Pcyt1a Gbp2 LOC100044129 Cldn16
Mcpt8 Prl8a9 Zdhhc9 Ubxn11 Myot Zfp93
Zfp93 Lhcgr Cldn1 Bcl6 Prl8a9 Olfr554
Slc19a1 Vwa2 Mcpt8 Snapc4 Vwa2 Fhod1
Dok5 Ccl27 Slc19a1 5430407P10Rik Ccl27 Gch1
Olfr554 Cml2 Dok5 Cldn16 Cml2 Cyp2c65
Th Actr3 Olfr884 Olfr1353 Cd209e Mageb1
Acss2 Cd209e Myot Lhcgr Ran Atmin
Idh3b Ran Egfl7 Fhod1 Mobkl2a Aldh5a1
Egfl7 Mobkl2a EG331493 Lrrc50 H3f3a Prss29
Nudcd1 Rxfp1 LOC100047837 Cyp2c65 Fut11 Rdh20
EG331493 Gm1961 Ntrk3 Mageb1 Rxfp1 Mink1
LOC100047837 LOC100047339 Fut11 Cdipt LOC100047339 Moxd1
Ntrk3 Hsd17b12 1700001O22Rik Abcb9 Hsd17b12 Olfr1276
1700001O22Rik Nr2f6 Slc2a1 Atmin 1300017J02Rik Klk13
Mybl1 1300017J02Rik Slc15a2 Prss29 Slc11a1 Acss2
Slc2a1 5430407P10Rik Vapb Rdh20 Fusip1 Men1
Trim26 Slc11a1 Suv39h2 Mink1 Tmem43 Gstm1
Slc15a2 Fusip1 Nab1 Moxd1 1810055E12Rik Mdh1
Cyp4f16 Tmem43 2510040D07Rik Olfr1276 Lpin1 Th
Vapb Gbp2 Bves Klk13 Pcyt1a Ccr8
Nab1 1810055E12Rik Trim41 Nr2f6 AW146020 Stk38
2510040D07Rik Lpin1 Ctps Men1 Slc9a1 Cyp4f16
Pcyt1a Cdipt Ars2 Gstm1 Olfr126 9630058J23Rik
Snapc4 Sfrs1 Mdh1 Tbrg1 Trim41
AW146020 Sfrs2 Ccr8 Suv39h2 Mettl6
Lrrc50 Tyms Stk38 Gcgr Dpysl2
Slc9a1 E2f1 9630058J23Rik Fcer1a Nbl1
Olfr126 Pgp Mettl6 1110001J03Rik Defb36
Tbrg1 Zw10 Dpysl2 Olfr1246 Trim26
Gadd45a Nbl1 Kif4 Serbp1
Gcgr Ppa2 Egf Lef1
Krt8 Defb36 Ctsd Mybl1
Fcer1a Serbp1 Psg23 Abcb4
1110001J03Rik Lef1 Tnpo1 Hibadh
Olfr1246 Actr3 Fbxo44 BC038613
Kif4 Abcb4 Rock1 Shisa3
Egf Gm1961 Rpl4 Tspyl3
Ctsd Hibadh EG13909 EG667977
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Table 1 Gene array results of EPC cell lines (Continued)
Psg23 Shisa3 Actr3 Gadd45a
Tnpo1 EG667977 Gm1961 Krt8
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http://www.molecular-cancer.com/content/13/1/177systemic injection of EPC_acLDL cells versus control tu-
mors. Figure 7D is the quantification of mean vessel
density between the two groups. Tumor blood vessel
density was significantly increased in the EPC_acLDL
injected animals compared to the control animals. Vas-
cularity was enhanced in both central tumor regions as
well as at the periphery (data not shown). These data
suggest that systemic injection of EPC_acLDL cells en-
hances tumor cell growth by increasing the tumor vas-
cular network.
Discussion
The selection of immunophenotypic markers of EPCs with
respect to the model system used is critical [32]. While
CD34 has been used previously to identify a human cell
population with clonogenic potential, it can also be highly
expressed on hematopoietic stem cells as well in some ma-
ture endothelial cells [33]. Similarly, the CD133 antigen has
also been identified as a stem cell marker in humans, but it
also commonly labels human hematopoietic stem cells and
its role in a mouse model is uncertain [34]. However, the c-
Kit antigen has been proposed as a murine marker of cells
with clonogenic potential and to potentially identify circu-
lating endothelial cells [35]. Recent data from Fang and col-
leagues, using a murine model, defined a rare population of
c-Kit+ cells that were able to self-renew and found that a
single, transplanted c-Kit + cell was able to proliferate and
formed part of the vascular network [30]. Similarly, Fazel
et al. demonstrated that c-Kit+ cells were recruited from
the bone marrow to infarct border zones in cardiac tissue
in a mouse model of myocardial infarction and promoted
cardiac repair [36]. While CD45 is often used as a marker
of true hematopoietic cells, the negative population can be
used to screen out non-hematopoietic cell populations [37].
Finally, Flk-1 (VEGFR-2) is a common marker of matureendothelial cells as well as endothelial progenitor cells
[33]. Based on these considerations, we isolated the
Flk-1+/c-Kit+/CD45- population to capture a circulat-
ing non-hematopoietic cell population with both stem
cell-like features as well as mature endothelial func-
tions in a mouse model system. These same markers
were also used by Shaked and colleagues in their stud-
ies of the mobilization and colonization of circulating
endothelial progenitor cells following treatment with
vascular disrupting agents and chemotherapy [17,38].
In the original studies of EPCs, circulating monocytic
populations were isolated by attaching to flasks and then
analyzed by flow cytometry to verify immunophenotypic
markings [1]. However, using a broad monocytic popula-
tion for the initial selection and growing the cells ex vivo in
supplemental media may have generated non-physiologic
conditions prior to marker analysis. This could result in the
selection of a heterogeneous population with a diverse
immunophenotypic expression profile that may not be re-
flective of the in vivo system. Our approach of using flow cy-
tometry first to identify the immunophenotypic markers
and then sorting viable cells to ex vivo culture conditions
should identify an enriched, homogeneous EPC population
that reflects the physiologic state of the tissue sampled. Add-
itionally, we confirmed that isolated cells grown ex vivo
maintained their immunophenotypic expression patterns
during low passage numbers.
We found that EPCs are present in most mouse tis-
sues, albeit at very low levels. While adipose tissue ap-
peared to have the highest concentration of EPC at
approximately 6.50%, these samples required multiple
adipose tissue sites (i.e. abdominal, mesenteric, and renal
fat pads) from multiple mice to generate sufficient num-
bers of cells to be analyzed by flow cytometry in our
young mice. Other mouse organs had very low levels of
Figure 7 EPC effects the vasculature in U251 xenografts. (A) U251 Xenograft Growth Curve: Local injection of U251 only (red) or U251 tumor
cells combined with EPC_acLDL cells (blue) at day 0 (arrow); Tumor Efficiency: Control 3/5 tumors; EPC_acLDL 5/5 tumors (n=5, each arm)
(B) U251 Xenograft Growth Curve: Systemic injection (1:10) of U251 only (red) or U251 tumor cells combined with EPC_acLDL cells (blue) at
day 7 (arrow); Tumor Efficiency: Control 4/5 tumors; EPC_acLDL 6/6 tumors (n=5-6, each arm) (C) U251 tumor xenografts with systemic
injection of EPC_acLDL (1:10 ratio) collected at day 28: Representative slides stained: red, CD31; blue, Hoechst's 33258. (D) Quantification of
Mean Vessel Density: Mean number of CD31+ pixels per 0.1 mm2 and standard deviation between control tumors and tumors with systemic
injection of EPC_acLDL (n=3).
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lung tissue sites having the highest expression of around
0.5%. Interestingly, samples from circulating blood and
brain tissue sites had the lowest levels of EPCs present.
Our study only examined resident EPCs in female nude
immunodeficient mice; whether these findings are simi-
lar in immunocompetent mice remains to be evaluated.
While EPCs are part of a very small cell population, theycould clearly be detected above background levels when
compared to unstained, isotype controls. Additionally,
the low levels of EPCs present in our model system is in
agreement with most previously published studies
[1,25,33,39,40]. An elegant study by Peters et al. found
that in human patients that have undergone bone mar-
row transplants and subsequently developed solid tu-
mors, bone marrow-derived cells contributed to tumor
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5.0% [26]. Our data also confirmed localization of resi-
dent EPCs to a variety of tumor types and that the EPCs
are derived from the host animal and are not the result
of “trans-differentiation” of the implanted tumor cells.
The elevated EPC concentration in adipose tissue is
also consistent with findings from other investigators.
Grenier et al. isolated a tissue-resident cell population
from adipose tissue that demonstrated the ability to gen-
erate stem-like spheres in culture and expressed the
Sca1+ stem cell marker [41]. Additionally, as this popu-
lation differentiated in vitro, they expressed Flk-1 and
CD31, were able to take up acLDL, and enhanced vascu-
logenesis during muscle regeneration. A study by Yang
et al. demonstrated that murine white adipose tissue
contains a population of stem cells that can be recruited
to tumor cells and enhance human tumor xenograft
vascularization and growth [42]. Finally, Martin-Padura
and colleagues demonstrated significant enrichment of
CD34+/CD45- stem cells in adipose tissue over that of
the bone marrow and that adipose stem cells could en-
hance tumor vascularization and growth in human
tumor xenografts in mice [43]. One of the limitations of
our study was the inability to find the correct in vitro
culture conditions to grow the adipose-derived Flk-1+/c-
Kit+/CD45- cell population in order to have stable
populations to use for additional experiments. Adipose-
resident EPCs could be a significant contributor to
circulating EPCs (i.e. a second reservoir besides bone
marrow), but additional studies with obese mouse models
(to enrich the source tissue) and/or the use of
fluorescently-labelled adipose tissue transplants would be
required to answer these questions.
Prior studies have used colony forming and matrigel
assays to define cell populations with both stem-like and
mature endothelial functions. Our results demonstrate
that the original Flk-1+/c-Kit+/CD45- EPC cell line as
well as the enriched EPC_acLDL population maintain
both of these characteristics. The high passage cell line
EPC_Late appears to lose the ability to generate colonies
in methylcellulose, but is able to form capillary-like
structures on matrigel. This is consistent with our flow
cytometry data indicating a decrease in c-Kit expression
in the EPC_Late cell line. All three cell lines expressed
CD31 and were able to take up the acLDL marker, indi-
cating mature endothelial function.
With these populations established, we asked a novel
question of whether these cell lines could prevent animal
death in a bone marrow transplant model. We hypothe-
sized that a true EPC population (considered to be
downstream of the hemangioblast and a separate cell
line from hematopoietic cells) would not be able to re-
generate the hematopoietic cell lines. However, after
whole body ionizing radiation, transplants of the EPCand EPC_acLDL cell lines did allow the bone marrow to
recover, indicating that our EPC and EPC_acLDL popu-
lations had hematopoietic potential. Interestingly, the
EPC_Late cell population was only partially able to sup-
port bone marrow recovery. Several other laboratories
have also observed the effect of endothelial cells sup-
porting the survival of bone marrow cells in vitro
[44-47]. Chute and colleagues also demonstrated that
Flk-1+ primary mouse brain endothelial cells injected
systemically after whole body irradiation resulted in ap-
proximately 60% mouse survival compared to 0% of the
controls and suggested that endothelial cell-derived
hematopoietic activity was responsible [48]. Similarly,
Montfort et al. found that transplantation of aorta or
vena cava segments into lethally irradiated mice also
provided a radioprotective effect [49]. At this time, it is
unclear if the injected EPCs differentiate into hematopoietic
cells or if perhaps cytokines produced by the EPCs can pro-
vide a protective response (“providing a vascular niche”) to
bone marrow cells and/or accelerates bone marrow recov-
ery [50]. Further studies are necessary to elucidate the
mechanism(s) of bone marrow recovery.
In our genetic analysis we found that the three cell
lines were quite similar with the greatest differences be-
ing between the original EPC cell line and the EPC_Late
cell line and similar sets of genes were up and down reg-
ulated between the cell lines. One gene of interest that
stood out was Sox2, a known stem cell marker. Sox2
was expressed at highest levels in the original cell line
EPC and was down regulated in the enriched EPC_acLDL
population and was further downregulated in the more
differentiated cell line, EPC_Late. These studies estab-
lished the close similarities of the derived cell lines; the ex-
ploration of any specific gene involvement in EPC
function remains to be investigated in future studies.
To determine the impact of EPCs on tumor growth
and vascularization, we demonstrated that a local injec-
tion of an EPC and tumor cell mixture as well as the
systemic injection of EPCs resulted in enhanced tumor
initiation and growth. The quantity of circulating EPCs
is considered to be quite low, averaging <5% with most
reports suggesting <2% [26,29,39]. We used a 10% ratio
of the EPC_acLDL cell line to the tumor cell line to re-
flect the lower physiologic concentration of circulating
EPCs. Martin-Padura et al. used a 20% ratio when inject-
ing harvested CD34+ progenitors from adiopose tissue
and combined with MDA-MB-436 cells and injecting
into mammary fat pads [43]. Similarly, He et al. also
used a ratio of 20% when injecting harvested bone mar-
row cells with RM1 mouse prostate cancer cells into
flanks of C57BL/6 mice [51]. Thus, while our system
may not reflect the ideal physiologic system, our ratio of
1:10 is consistent and slightly more restrictive than prior
studies. Systemic injection of the enriched EPC_acLDL
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the tumors as demonstrated by CD31+ staining. Whether
injected EPCs directly established new vasculature or con-
tributed to vascular growth through the expression of
proangiogenic cytokines will need to be addressed in fu-
ture studies. In examining the contribution of circulating
EPCs toward the development of tumor blood vessel,
Lyden et al. demonstrated that in bone marrow ablated
mice, bone marrow transplant rescued tumor angiogenesis
in mice that did not express a key enzyme of endothelial
cell function, nitric oxide synthase [13]. In contrast,
DePalma et al. failed to find transplanted bone marrow
cells expressing a labeled TIE-2 promoter within tumor
vasculature [39]. Similarly, Purhonen et al. used a labeled
parabiosis mouse model to establish collateral circulation
but failed to find labeled bone marrow-derived cells in the
partner mouse tumor vasculature, though a few bone
marrow-derived cells were present in the perivascular
niche [29]. However, several additional studies have found
that tumor grade, tumor type, as well as the tumor site of
origin may regulate the incorporation of circulating EPCs
into tumor-associated blood vessels [52-54].
Finding a specific cell type, such as EPCs, that directly
influences tumor growth and vascularization may have a
substantial clinical impact. These cells may influence
tumor resistance to chemotherapy or radiation treat-
ment and may help promote tumor recovery after surgi-
cal resection. Thus, understanding EPCs will provide
benefit as a possible therapeutic target. However, prior
EPCs studies have presented a spectrum of conflicting
results. In our study we have focused on circulating Flk-
1+/c-Kit+/CD45- which have clearly demonstrated EPC
function. We acknowledge that there may be alternative
immunophenotypic markers that define other cell popu-
lations with EPC functionality. We have further estab-
lished that the Flk-1+/c-Kit+/CD45- population, even at
the low level of circulating cells identified in this study
and others, can play a significant role in tumor growth
and tumor vascularization. Additionally, a novel prop-
erty found in this study was the hemangioblastic poten-
tial of the Flk-1+/c-Kit+/CD45- cell population and this
ability could significantly impact tumor survival. The full
contribution of this finding remains to be elucidated.
Given the potential for EPCs to support tumor growth,
they may also contribute to the resistance of tumors
during treatment. Additional studies are ongoing to ad-
dress the contribution of EPCs to resistance mechanisms
as well as the consideration of an anti-EPC strategy to
enhance current anti-neoplastic therapies.
Conclusions
In summary, our current study has identified Flk-1+/C-
Kit+/CD45- cells as endothelial progenitor cells with
both endothelial and stem-like qualities. Furthermore,circulating EPCs enhance tumor initiation, tumor growth,
and increase tumor vascularity. Future studies will investi-
gate the origins of EPCs and determine their role in medi-
ating resistance to anti-cancer therapies.
Materials and methods
Antibodies and reagents
Selected antibodies were acquired as indicated: Rat IgG
Isotype control (553993, BD Pharmingen), Rat IgG
Fluorescent Isotype controls (sc-2831, sc-3788, sc-2895,
sc 2872; Santa Cruz Biotechnology), Rat Anti-Mouse
Flk-1-PE (555308, BD Pharmingen), Rat Anti-Mouse
c-Kit-PE-Cy7 (558163, BD Pharmingen), Rat Anti-Mouse
CD45-APC-Cy7 (557659, BD Pharmingen), Rat Anti-
Mouse CD31-FITC (553372, BD Pharmingen), Mouse
Anti-Human VEGFR2-PE (560872, BD Pharmingen),
Mouse Anti-Human CD117-APC (561118, BD Pharmin-
gen), Mouse Anti-Human CD45-APC-Cy7 (557833, BD
Pharmingen), Mouse Anti-Human CD31-FITC (560984,
BD Pharmingen), Rat Anti-Mouse CD31 (550274, BD
Pharmingen), Goat Anti-Rat FITC (sc-2011, Santa Cruz
Biotechnology), Goat Anti-Rat AlexaFluor594 (A-11007,
Life Technologies), Anti-Rabbit Oct-4 (AB3209, EMD
Millipore), and Goat Anti-Rabbit FITC (sc-2012, Santa
Cruz Biotechnology). Additional reagents used: Hoechst’s
33258 Stain (94403, Sigma-Aldrich), acLDL-Dil (L3484,
Life Technologies), acLDL-BODIPY (L3485, Life Tech-
nologies), acLDL (L35354, Life Technologies), Fibronectin
(F1141, Sigma-Aldrich), and Alkaline Phosphatase Stain
(A14353, Life Technologies).
Cell lines
HUVECs were grown in human endothelial growth media
with supplementation (PM211500, Genlantis, San Diego,
CA). The tumor cell lines: A549 lung carcinoma, U251
glioblastoma, and UMSCC-1 head and neck squamous
cell carcinoma were grown in DMEM supplemented with
10% inactivated fetal bovine serum (Life Technology) and
1% penicillin-streptomycin. All cell lines were acquired
from ATCC (Manassas, VA).
Mice
Female athymic nu/nu nude mice (aged 8–12 weeks)
were acquired from NCI-Fredrick (Fredrick, MD). Mice
were maintained in a germ-free environment and had
access to food and water ad libitum. All animal proce-
dures were approved by Stanford University’s Adminis-
trative Panel on Laboratory Animal Care (APLAC).
Mouse xenografts
Tumors were implanted subcutaneously on the backs of
nude mice approximately 2 cm above the base of the tail.
A549, U251, and UMSCC-1 cell lines were implanted at
a concentration of 3×106 cells in 100 μL PBS. Tumors
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with an efficiency of approximately 90%, 70%, and 90%,
respectively.
EPCs isolation
EPC isolation was performed as reported previously with
documented modifications [1,55,56]. Selected mouse tis-
sues or tumor samples were surgically removed from eutha-
nized nude mice. Tissues were kept in mouse endothelial
media (M1168, CellBiologics, Chicago, IL) supplemented
with the growth factor kit (VEGF, EGF, heparin, hydrocorti-
sone, and L-Glumatine) and 10% fetal bovis serum (FBS)
and then minced into small chunks with a #11 scalpel blade.
Tissue fragments were then placed into a glass homogenizer
and mechanically disrupted into cellular slurry. The slurry
was transferred to 15 mL tubes and mixed with 1 mL of
supplemented mouse endothelial media and combined with
2 mL of 0.1% Collagenase I (CLS-1, Worthington Biochem,
Lakewood, NJ), 0.1% Collagenase IV (CLS-4, Worthington
Biochem, Lakewood, NJ), and 0.001% Deoxyribonuclease I
(DPRF, Worthington Biochem, Lakewood, NJ). Samples
were incubated for 30 minutes at 37°C. Mouse endothelial
medium was added to a total volume of 15 mL and solu-
tions were poured through a 70 μM cell strainer into a new
15 mL tube. Tube were then spun at 4°C at 3000 rpm for
5 minutes. The supernatant was decanted and the resulting
cell pellet was resuspended in 2 mL of RBC lysis buffer
(1.5 M NH4CL, 100 mM NaHCO3, 10 mM Na2-EDTA;
pH 7.4) and placed on ice. After 15 minutes, samples were
spun down at 4°C at 3000 rpm for 5 minutes, supernatant
removed, and resuspended in PBS and kept on ice. Live/
Dead stain (L23105, Invitrogen) was added to the cells for
30 minutes with cells kept on ice and protected from light.
Samples were then moved to eppendorf tubes and spun for
5 minutes, 4°C at 5000 rpm. Supernatant was removed and
the cell pellet was washed twice in PBS, and resuspended in
PBS and used for flow cytometry.
Flow cytometry
Flow cytometry was performed in the Stanford Flow
Cytometry Core Facility using the BD Aria II (sorting)
or BD LSR.II (analysis). Samples were isolated from
mouse tissues or tumors as above or from trypsinized
from tissue culture samples. Cells were blocked with
CD16/CD32 Mouse Fc Block (553142, BD Pharmin-
gen) for 30 minutes, then labeled with anti-Flk-1:PE,
anti-c-Kit:PE-Cy7, anti-CD45: APC-Cy7, and as indi-
cated, anti-CD31: FITC. Unstained samples and sam-
ples with antibody IgG controls were run in parallel.
Additionally, color compensation for each fluorochrome
was evaluated using IgG compensation beads (552843, BD
Pharmingen) and ArC compensation beads (A10346,
Invitrogen) with appropriate fluorescent marker con-
trols. Once lasers were tuned and color compensationwas set, at least 100,000 cells per sample were run, ex-
cept for the adipose tissue samples which were run at
50,000 cells per sample. Gating was initially applied to
isolate single cell populations of viable cells, then add-
itional gating was used to select for the appropriate
subpopulations (Flk-1+/c-Kit+/CD45-). Flow cytometric
analysis was performed using FlowJo Software (TreeStar,
Inc., Ashland, OR). For the flow cytometry sorting of live
cells, the same staining process was used as above. Once
subpopulations of single, viable cells were gated on Flk1+,
c-Kit+, and CD45- and subsequently isolated, they were
then collected in an eppendorf tube with 500 μL of mouse
endothelial media (M1168, Cell Biologics, Chicago, IL)
supplemented with the growth factor kit (VEGF, EGF,
heparin, hydrocortisone, and L-Glumatine) and 10% FBS
and managed as in vitro cultures as described below.
In vitro culturing of sorted EPCs
Sorted cell from nude mouse lung samples were placed
in 5 μg/cm2 fibronectin treated T25 flasks in mouse
endothelial medium (M1168, Cell Biologics, Chicago, IL)
supplemented with the growth factor kit (VEGF, EGF,
heparin, hydrocortisone, L-Glumatine, and 10% FBS)
and incubated at physiologic concentrations of FiO2
(5%) at 37°C. Flasks were examined every 2–3 days and
once attached cells began to generate colonies of 10–20
cells, flasks were moved to normoxic incubators (FiO2
21% at 37°C). As flasks became confluent, cells were
passaged as usual. The EPC cell line and EPC_acLDL
cell lines were used from passages 3–6 and the
EPC_Late cell lines was used between passages 16–24.
ICC immunofluorescence
Tumor and EPC cell lines were grown and treated in
chamber slides (C1782, Sigma-Aldrich). The reagent
acLDL-Dil or acLDL-BODIPY was mixed with cells at
2.5 μg/mL concentration and allowed to incubate for
4 hours at 37°C. Medium was then aspirated and cells
were fixed in 4% paraformaldehyde for 10 min at room
temperature. Paraformaldehyde was aspirated and the
cells treated with a 0.2% NP40/PBS solution for 15 min.
HUVEC cells and the human tumor cell lines used
acLDL-BODIPY and the Anti-CD31-APC antibody while
the murine derived EPC-related cell lines used acLDL-
Dil and the Anti-CD31-FITC antibody for staining. Cells
were then washed in PBS twice, and the selected anti-
CD31 antibody at a dilution of 1:50 in 1% BSA was
added and incubated overnight at 4°C. Cells were again
washed twice in PBS before incubating in the dark with
the appropriately labeled secondary antibody at a dilu-
tion of 1:100 in 1% BSA for 1 h. The secondary antibody
solution was then aspirated and the cells washed twice
in PBS. Cells were then incubated in the dark with
Hoechst’s 33258 (1 μg/ml) in PBS for 30 min, washed
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(Dako Corp., Carpinteria, CA) and sealed with clear nail
polish. Slides were examined on a Lecica DM6000B
fluorescent microscope (Lecica, Buffalo Grove, IL). Im-
ages were captured by a CCD camera using the Image
Pro Premier v9.0 (MediaCybernetics, Rockville, MD)
software package.
IHC immunofluorescence
Tissues were harvest from mice and placed in cassettes
and covered in OCT media. Cassettes were held
at −80°C until they were process on a cryotome and cut
to 2 μm tissue sections. Slides were then kept at −80°C
until processing. Slides were allowed to air dry for
10 min at room temperature and then were kept
in −20°C methanol for 10 minutes. Methanol was re-
moved and samples were allowed to air dry for 30 mi-
nutes and washed with PBS twice for 5 minutes each.
The rat anti-CD31 antibody was used at a dilution of
1:20 in 2% BSA and incubated overnight at 4°C. Slides
were again washed twice in PBS before incubating in the
dark with a goat anti-rat AlexaFluor594-labeled second-
ary antibody at a dilution of 1:100 in 1% BSA for 1 h.
The secondary antibody solution was then aspirated and
the cells washed twice in PBS. Cells were then incubated
in the dark with Hoechst’s (1 μg/ml) in PBS for 30 min,
washed twice, and coverslips mounted with an anti-fade
solution (Dako Corp., Carpinteria, CA) and slides were
sealed with clear nail polish. Slides were examined and
images captured as above.
Colony forming assay
Selected cell lines were cultured in methylcellulose-
containing medium (M3434, StemCell Technologies,
Vancouver, BC, Canada) with 50 ng/mL vascular endo-
thelial (VE) growth factor (R&D Systems, Minneapolis,
MN, USA), 50 ng/mL basic fibroblast growth factor
(Wako, Osaka, Japan) and 10% fetal bovine serum (FBS)
on 35-mm dishes. Cell densities were 1×103 for each cell
lines. Dishes were plated in triplicate and kept in hu-
midified incubator for 8–10 days until colonies started
to develop. EPC colony forming units (CFUs) were de-
fined as cluster-like collections of cells associated with
attached spindle-shaped cells. The EPC-CFUs were iden-
tified by visual inspection with an inverted microscope
under 20-40× magnification. Images were acquired on a
Zeiss Observer. A1 (Zeiss Microscopy, Thornwood, NY)
microscope using AxioVision 4.6.3 software (Zeiss Mi-
croscopy, Thornwood, NY).
Matrigel assay
As a modified protocol of Wu et al., matrigel (356237,
BD Pharmingen) was applied in thin layers to wells of
24-well plates [57]. Cells of selected cell lines wereplaced at indicated cellular concentrations: 1×104, 1×105,
and 1×106 cells. Cells were incubated overnight and the
next morning (18 hrs) evaluated under light microscopy
at 20-40X magnification. Images were acquired on a
Zeiss Observer. A1 (Zeiss Microscopy, Thornwood, NY)
microscope using AxioVision 4.6.3 software (Zeiss
Microscopy, Thornwood, NY).
Bone marrow transplant studies
Nude mice were exposed to two doses of 4.5 Gy given
4 hours apart and, as indicated, supplemental cells were
given 2 hours after the final radiation dose [58]. Normal
bone marrow was collected from unirradiated 12–16
week old mice by isolating the femurs and tibia, cutting
the end from the bone, and then flushing out the central
cavity using 28 gauge needles with 2% FBS in Hank’s bal-
anced salt solution. The cell solution was collected, spun
down, and cell concentration calculated. Harvested bone
marrow or the selected ex vivo cultured EPC cell lines
were injected into the retro-orbital venous plexus of an
anesthetized mouse at 3×106 cells in 100 uL PBS. Sur-
vival was assessed every two days and mice were sacri-
ficed if weight had dropped more than 10% per animal
protocol guidelines.
Gene array analysis
Sorted cell lines: EPC, EPC_acLDL, and EPC_late were
grown out, collected, and RNA isolated (RNeasy mini
kit, Qiagen). RNA concentration and quality was mea-
sured by NanoDrop analysis. RNA was stored in RNAase
free water at −80°C until analysis. RNA was hybridized
to MouseRef-8 v2.0 Beadchips (25 K, Illumina, San
Diego, CA). Two separate experiments were performed
independently and run in duplicate at the Stanford Gene
Array Core Facility. Bead level intensity values were sum-
marized without normalization and local background cor-
rection was applied by default using Beadstudio v3.1.
Microarray gene expression data were processed and ana-
lyzed using Genespring VX (Agilent, Santa Clara, CA).
Clustering was performed using non-centered Pearson
correlation. Data was deposited at: http://www.ncbi.nlm.
gov/projects/geo (GSE53681).
Tumor growth curves
U251 cells at a concentration of 3 × 106 were mixed with
3×105 EPC_acLDL cells (10% ratio). For co-injection
studies, the cell mixture was implanted on the back of
nude mice and tumor measurements were taken ap-
proximately three times a week. Tumor volume (mm3)
was calculated as (height2*length)/2. For the systemic in-
jection studies, Tumors (U251; 3×106) were implanted
on the back of mice on day 0 and EPC_acLDL cells (3 ×
105) were given by 100 μL retro-orbital injection on day
7 with controls receiving an injection of normal saline in
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taken approximately three times weekly and tumor vol-
umes calculated as above. Numeric data are presented as
the mean +/− standard error.
Mean vessel density analysis
Images from the fluorescent immunohistochemical analysis
were imported into ImageJ analysis software (http://www.
rsbweb.nih.gov/ij/, NIH, Bethesda, MD). A threshold of
CD31 pixel intensity was applied to all images and the total
number of CD31 positive pixels was counted within the
field of view. Total CD31 pixel counts from five random
images from each tumor sample were analyzed and aver-
ages were calculated over a 0.1 mm2 area [59,60]. Two
tumors from two different experiments were used for
analysis. Numeric data are presented as the mean +/−
standard deviation.
Statistical analysis
Statistical comparisons of datasets were performed by a
two-tailed Student’s T-test using Microsoft Excel (Redmond,
Washington). Data was considered to be significantly differ-
ent when P ≤ 0.05.
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